Search

CRISPR Therapeutics AG

Закрыт

СекторЗдравоохранение

53.5 -0.91

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

52.01

Макс.

53.83

Ключевые показатели

By Trading Economics

Доход

-91M

-214M

Продажи

8.7M

10M

Прибыль на акцию

-0.94

Рентабельность продаж

-2,102.79

Сотрудники

393

EBITDA

7.3M

-110M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+37.67% upside

Дивиденды

By Acuity

Следующий отчет о доходах

9 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

572M

5.2B

Предыдущая цена открытия

54.41

Предыдущая цена закрытия

53.5

Новостные настроения

By Acuity

32%

68%

112 / 340 Рейтинг в Healthcare

CRISPR Therapeutics AG График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

14 авг. 2026 г., 19:16 UTC

CRISPR Therapeutics AG shares are lower today amid broader investor caution following a decline in U.S. retail sales for July.

13 авг. 2026 г., 23:46 UTC

Correlated Moves

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting a positive trend in the biotechnology sector amid favorable economic conditions.

11 авг. 2026 г., 19:21 UTC

CRISPR Therapeutics AG shares are trading higher amid rising oil prices and inflation concerns ahead of upcoming U.S. inflation data. No specific news was identified.

10 авг. 2026 г., 23:06 UTC

No specific news was identified for CRISPR Therapeutics AG, which traded roughly flat during after-market hours, remaining near the upper end of its one-month range.

7 авг. 2026 г., 20:06 UTC

News
Correlated Moves
Social Media

CRISPR Therapeutics AG is gaining amid positive social media sentiment and bullish chart patterns, aligning with the upward trend in the ARK Genomic Revolution ETF.

6 авг. 2026 г., 22:06 UTC

Correlated Moves

CRISPR Therapeutics AG shares are higher in after-market hours, aligning with positive trends in the biotechnology sector and maintaining a position above its 20-day moving average.

5 авг. 2026 г., 23:16 UTC

CRISPR Therapeutics AG shares traded lower in after-market hours, settling above the 20-day moving average and within the middle of its one-month range.

4 авг. 2026 г., 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, following a volatile session with no specific news identified to explain the movement.

3 авг. 2026 г., 23:02 UTC

Social Media
News

CRISPR Therapeutics reported second-quarter revenue of $10.18 million, exceeding expectations. Shares are trading higher in after-market hours following the earnings report.

31 июл. 2026 г., 23:06 UTC

Shares of CRISPR Therapeutics AG are trading higher in after-market hours. The stock remains near the lower end of its one-month trading range.

30 июл. 2026 г., 23:02 UTC

News

CRISPR Therapeutics shares are lower in after-market hours amid broader market weakness, despite analysts projecting revenue growth and a price target of $83.53.

29 июл. 2026 г., 22:01 UTC

CRISPR Therapeutics AG shares are lower in after-market trading amid broader market declines driven by geopolitical tensions and caution ahead of the Fed's interest rate decision.

28 июл. 2026 г., 23:01 UTC

Correlated Moves

CRISPR Therapeutics AG shares are lower in after-market trading, reflecting broader market trends and a decline in the Russell 2000 Index.

27 июл. 2026 г., 19:07 UTC

CRISPR Therapeutics AG shares are higher today, gaining since Friday's close. The stock peaked earlier in the session before pulling back.

23 июл. 2026 г., 10:36 UTC

CRISPR Therapeutics AG shares are roughly flat in pre-market hours, with no specific company news identified. The stock remains near the lower end of its trading range.

22 июл. 2026 г., 23:06 UTC

CRISPR Therapeutics AG shares are trading higher in after-market hours, though they remain below their 20-day moving average and near the lower end of their one-month range.

21 июл. 2026 г., 19:26 UTC

News
Correlated Moves

CRISPR Therapeutics AG shares are higher today, buoyed by a strong gene-editing pipeline and positive analyst sentiment regarding its lead asset, CASGEVY.

20 июл. 2026 г., 23:22 UTC

CRISPR Therapeutics AG is trading higher in after-market hours, despite broader market declines linked to rising treasury yields. No specific news was identified.

Сравнение c конкурентами

Изменение цены

CRISPR Therapeutics AG Прогноз

Целевая цена

By TipRanks

37.67% рост

Прогноз на 12 месяцев

Средняя 74.33 USD  37.67%

Максимум 110 USD

Минимум 45 USD

Основано на мнении 13 аналитиков Wall Street, спрогнозировавших целевые цены для CRISPR Therapeutics AG на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

13 ratings

8

Покупка

5

Удержание

0

Продажа

Настроения

By Acuity

112 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
help-icon Live chat